Trevi Historical Balance Sheet

TRVI Stock

USD 2.91 0.18 6.59%

Trend analysis of Trevi Therapeutics balance sheet accounts such as Other Liabilities of 2.6 K, Net Tangible Assets of 129.8 M, Total Permanent Equity of 0.0 or Noncontrolling Interest In Consolidated Entity of 0.0 provides information on Trevi Therapeutics' total assets, liabilities, and equity, which is the actual value of Trevi Therapeutics to its prevalent stockholders. By breaking down trends over time using Trevi Therapeutics balance sheet statements, investors will see what precisely the company owns and what it owes to creditors or other parties at the end of each accounting year.

Cash Flow Balance Sheet Income Statement

Covid

Financial Statement Analysis is much more than just reviewing and examining Trevi Therapeutics latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Trevi Therapeutics is a good buy for the upcoming year.

Trevi Therapeutics Inventory

(263,292)

Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Trevi Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real.

For more detail on how to invest in Trevi Stock please use our How to Invest in Trevi Therapeutics guide.

About Trevi Balance Sheet Analysis

Balance Sheet is a snapshot of the financial position of Trevi Therapeutics at a specified time, usually calculated after every quarter, six months, or one year. Trevi Therapeutics Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of Trevi Therapeutics and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which Trevi currently owns. An asset can also be divided into two categories, current and non-current.

Trevi Therapeutics Balance Sheet Chart

As of now, Trevi Therapeutics' Other Current Assets are increasing as compared to previous years. The Trevi Therapeutics' current Total Liabilities is estimated to increase to about 10.6 M, while Total Assets are projected to decrease to under 56.3 M.

Total Assets Other Current Liab Total Current Liabilities Other Liab Total Permanent Equity Current Deferred Revenue

Add Fundamental

Total Assets

Total assets refers to the total amount of Trevi Therapeutics assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Trevi Therapeutics books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.

Total Current Liabilities

Total Current Liabilities is an item on Trevi Therapeutics balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Trevi Therapeutics are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.

Current Deferred Revenue

Revenue that has been collected but not yet earned, typically from prepaid service contracts or subscriptions. This amount is considered a liability until the service is provided or the subscription period ends.

Most accounts from Trevi Therapeutics' balance sheet are interrelated and interconnected. However, analyzing balance sheet accounts one by one will only give a small insight into Trevi Therapeutics current financial condition. On the other hand, looking into the entire matrix of balance sheet accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Trevi Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real.

For more detail on how to invest in Trevi Stock please use our How to Invest in Trevi Therapeutics guide.As of now, Trevi Therapeutics' Other Current Assets are increasing as compared to previous years. The Trevi Therapeutics' current Total Liabilities is estimated to increase to about 10.6 M, while Total Assets are projected to decrease to under 56.3 M.

	2021	2022	2023	2024 (projected)
Other Current Liabilities	3.9M	3.5M	3.4M	3.2M
Total Assets	38.5M	123.0M	89.4M	56.3M

Other Current Liab Total Assets

Trevi Therapeutics balance sheet Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Other Liab	Net Tangible Assets	Retained Earnings	Accounts Payable	Cash	Other Assets	Long Term Debt	Cash And Short Term Investments	Net Receivables	Long Term Debt Total	Other Current Assets	Total Liab	Short Long Term Debt	Total Current Assets	Short Term Debt	Common Stock	Property Plant Equipment	Short Long Term Debt Total	Property Plant And Equipment Net	Net Debt	Non Current Assets Total	Non Currrent Assets Other
Total Assets		0.69	-0.54	0.98	-0.8	0.88	-0.86	0.83	0.48	-0.02	0.0	0.57	0.69	-0.02	0.67	-0.54	-0.2	1.0	-0.57	0.58	0.64	0.06	0.56	-0.2	0.48	0.1
Other Current Liab	0.69		-0.31	0.63	-0.83	0.82	-0.74	0.88	0.64	-0.14	0.53	0.59	0.72	0.31	0.5	-0.14	-0.02	0.69	-0.45	0.31	0.74	0.35	0.49	-0.44	0.38	0.02
Total Current Liabilities	-0.54	-0.31		-0.67	0.31	-0.5	0.6	-0.49	-0.77	-0.42	-0.08	-0.7	-0.76	-0.09	-0.4	0.92	0.81	-0.53	0.98	-0.67	-0.77	0.16	-0.54	0.54	-0.75	-0.6
Total Stockholder Equity	0.98	0.63	-0.67		-0.73	0.85	-0.85	0.79	0.54	0.08	-0.03	0.62	0.75	-0.03	0.66	-0.68	-0.34	0.98	-0.68	0.66	0.68	-0.04	0.59	-0.27	0.56	0.2
Other Liab	-0.8	-0.83	0.31	-0.73		-0.93	0.9	-0.88	-0.5	0.31	-0.1	-0.69	-0.55	0.08	-0.78	0.23	-0.03	-0.8	0.4	-0.29	-0.51	-0.27	-0.68	0.25	-0.43	0.15
Net Tangible Assets	0.88	0.82	-0.5	0.85	-0.93		-0.92	0.82	0.61	-0.25	0.15	0.81	0.72	0.09	0.83	-0.44	-0.12	0.88	-0.6	0.41	0.69	0.03	0.8	-0.43	0.59	-0.04
Retained Earnings	-0.86	-0.74	0.6	-0.85	0.9	-0.92		-0.85	-0.52	-0.04	0.07	-0.78	-0.62	0.19	-0.88	0.52	0.35	-0.85	0.66	-0.64	-0.6	-0.09	-0.81	0.24	-0.75	-0.25
Accounts Payable	0.83	0.88	-0.49	0.79	-0.88	0.82	-0.85		0.62	0.0	0.28	0.55	0.7	0.06	0.52	-0.33	-0.21	0.83	-0.55	0.44	0.7	0.47	0.43	-0.23	0.41	0.13
Cash	0.48	0.64	-0.77	0.54	-0.5	0.61	-0.52	0.62		-0.03	0.61	0.77	0.9	0.52	0.28	-0.59	-0.39	0.47	-0.82	0.24	0.93	0.08	0.49	-0.85	0.46	0.16
Other Assets	-0.02	-0.14	-0.42	0.08	0.31	-0.25	-0.04	0.0	-0.03		-0.28	-0.12	0.11	-0.34	-0.12	-0.45	-0.82	-0.03	-0.36	0.74	0.11	-0.19	-0.11	0.16	0.42	0.92
Long Term Debt	0.0	0.53	-0.08	-0.03	-0.1	0.15	0.07	0.28	0.61	-0.28		0.16	0.49	0.91	-0.32	0.17	0.19	0.0	-0.18	-0.32	0.6	0.39	-0.12	-0.62	-0.18	-0.17
Cash And Short Term Investments	0.57	0.59	-0.7	0.62	-0.69	0.81	-0.78	0.55	0.77	-0.12	0.16		0.71	0.12	0.79	-0.63	-0.38	0.56	-0.8	0.4	0.7	-0.22	0.93	-0.71	0.78	0.14
Net Receivables	0.69	0.72	-0.76	0.75	-0.55	0.72	-0.62	0.7	0.9	0.11	0.49	0.71		0.43	0.37	-0.69	-0.44	0.69	-0.82	0.46	0.97	-0.08	0.5	-0.77	0.51	0.23
Long Term Debt Total	-0.02	0.31	-0.09	-0.03	0.08	0.09	0.19	0.06	0.52	-0.34	0.91	0.12	0.43		-0.34	0.11	0.22	-0.01	-0.18	-0.36	0.55	0.16	-0.1	-0.63	-0.19	-0.2
Other Current Assets	0.67	0.5	-0.4	0.66	-0.78	0.83	-0.88	0.52	0.28	-0.12	-0.32	0.79	0.37	-0.34		-0.44	-0.21	0.67	-0.48	0.51	0.32	-0.24	0.94	-0.2	0.75	0.08
Total Liab	-0.54	-0.14	0.92	-0.68	0.23	-0.44	0.52	-0.33	-0.59	-0.45	0.17	-0.63	-0.69	0.11	-0.44		0.79	-0.53	0.87	-0.7	-0.61	0.46	-0.53	0.47	-0.69	-0.52
Short Long Term Debt	-0.2	-0.02	0.81	-0.34	-0.03	-0.12	0.35	-0.21	-0.39	-0.82	0.19	-0.38	-0.44	0.22	-0.21	0.79		-0.19	0.77	-0.78	-0.44	0.27	-0.31	0.22	-0.73	-0.89
Total Current Assets	1.0	0.69	-0.53	0.98	-0.8	0.88	-0.85	0.83	0.47	-0.03	0.0	0.56	0.69	-0.01	0.67	-0.53	-0.19		-0.56	0.57	0.63	0.07	0.56	-0.19	0.47	0.09
Short Term Debt	-0.57	-0.45	0.98	-0.68	0.4	-0.6	0.66	-0.55	-0.82	-0.36	-0.18	-0.8	-0.82	-0.18	-0.48	0.87	0.77	-0.56		-0.67	-0.84	0.16	-0.64	0.63	-0.81	-0.58
Common Stock	0.58	0.31	-0.67	0.66	-0.29	0.41	-0.64	0.44	0.24	0.74	-0.32	0.4	0.46	-0.36	0.51	-0.7	-0.78	0.57	-0.67		0.42	-0.25	0.47	-0.03	0.81	0.81
Property Plant Equipment	0.64	0.74	-0.77	0.68	-0.51	0.69	-0.6	0.7	0.93	0.11	0.6	0.7	0.97	0.55	0.32	-0.61	-0.44	0.63	-0.84	0.42		0.05	0.48	-0.77	0.52	0.29
Short Long Term Debt Total	0.06	0.35	0.16	-0.04	-0.27	0.03	-0.09	0.47	0.08	-0.19	0.39	-0.22	-0.08	0.16	-0.24	0.46	0.27	0.07	0.16	-0.25	0.05		-0.35	0.29	-0.33	-0.11
Property Plant And Equipment Net	0.56	0.49	-0.54	0.59	-0.68	0.8	-0.81	0.43	0.49	-0.11	-0.12	0.93	0.5	-0.1	0.94	-0.53	-0.31	0.56	-0.64	0.47	0.48	-0.35		-0.49	0.83	0.14
Net Debt	-0.2	-0.44	0.54	-0.27	0.25	-0.43	0.24	-0.23	-0.85	0.16	-0.62	-0.71	-0.77	-0.63	-0.2	0.47	0.22	-0.19	0.63	-0.03	-0.77	0.29	-0.49		-0.36	0.02
Non Current Assets Total	0.48	0.38	-0.75	0.56	-0.43	0.59	-0.75	0.41	0.46	0.42	-0.18	0.78	0.51	-0.19	0.75	-0.69	-0.73	0.47	-0.81	0.81	0.52	-0.33	0.83	-0.36		0.66
Non Currrent Assets Other	0.1	0.02	-0.6	0.2	0.15	-0.04	-0.25	0.13	0.16	0.92	-0.17	0.14	0.23	-0.2	0.08	-0.52	-0.89	0.09	-0.58	0.81	0.29	-0.11	0.14	0.02	0.66

Click cells to compare fundamentals

Trevi Therapeutics Account Relationship Matchups

Trevi Therapeutics balance sheet Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	60.0M	47.1M	38.5M	123.0M	89.4M	56.3M
Other Current Liab	3.5M	3.4M	3.9M	3.5M	3.4M	3.2M
Total Current Liabilities	5.2M	5.6M	12.7M	13.4M	5.8M	7.3M
Total Stockholder Equity	54.5M	27.3M	17.1M	107.5M	82.5M	41.7M
Other Liab	325K	460K	196K	3K	2.7K	2.6K
Net Tangible Assets	54.5M	27.3M	17.1M	107.5M	123.6M	129.8M
Retained Earnings	(114.2M)	(147.0M)	(180.9M)	(210.1M)	(239.1M)	(227.2M)
Accounts Payable	1.6M	2.0M	2.8M	2.9M	1.8M	1.7M
Cash	57.3M	45.0M	36.8M	12.6M	32.4M	31.8M
Other Assets	1.6M	19K	759.0	334K	205K	0.0
Cash And Short Term Investments	57.3M	45.0M	36.8M	12.6M	83.0M	87.1M
Net Receivables	184K	558K	265K	241K	277.2K	243.5K
Common Stock Total Equity	101K	18K	19K	60K	69K	37.0K
Inventory	1.4M	1.6M	895K	(241K)	(277.2K)	(263.3K)
Other Current Assets	77K	108K	886K	2.1M	4.6M	4.8M
Other Stockholder Equity	168.7M	174.2M	198.0M	317.6M	321.6M	179.7M
Total Liab	5.5M	19.8M	21.4M	15.6M	6.9M	10.6M
Short Long Term Debt	5.3M	0.0	5.8M	7M	6.3M	4.2M
Total Current Assets	59.6M	46.3M	38.0M	122.6M	87.5M	55.5M
Accumulated Other Comprehensive Income	(23K)	(46K)	(60.0M)	(122K)	(29K)	(30.5K)
Short Term Debt	99K	113K	6.0M	7.0M	612K	581.4K
Common Stock	18K	19K	29K	60K	68K	41.7K
Property Plant Equipment	430K	330K	184K	170K	195.5K	201.5K
Property Plant And Equipment Net	430K	330K	184K	194K	1.6M	1.6M
Net Debt	(57.0M)	(30.8M)	(22.2M)	(3.4M)	(31.1M)	(32.6M)
Non Current Assets Total	449K	862K	518K	399K	1.9M	1.9M
Non Currrent Assets Other	19K	532K	334K	205K	297K	341.9K
Common Stock Shares Outstanding	11.7M	18.1M	22.8M	64.5M	99.0M	104.0M
Liabilities And Stockholders Equity	60.0M	47.1M	38.5M	123.0M	89.4M	63.0M
Non Current Liabilities Total	257K	14.3M	8.7M	2.2M	1.0M	980.4K
Net Invested Capital	54.5M	41.2M	31.6M	116.6M	82.5M	41.6M
Property Plant And Equipment Gross	430K	330K	366K	419K	1.7M	1.8M
Net Working Capital	54.4M	40.7M	25.2M	109.2M	81.7M	53.8M
Capital Stock	18K	19K	29K	60K	68K	39.3K

Currently Active Assets on Macroaxis

RSI	Rush Street Interactive
OKTA	Okta Inc
BAC	Bank of America
S	SentinelOne
WD	Walker Dunlop

When determining whether Trevi Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Trevi Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Trevi Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Trevi Therapeutics Stock:

How To Invest In Trevi

Details

Is Trevi Stock a good investment?

Details

What is Trevi Therapeutics' Net Worth?

Details

Largest Pharmaceuticals Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

For more detail on how to invest in Trevi Stock please use our How to Invest in Trevi Therapeutics guide.

You can also try the Portfolio Dashboard module to portfolio dashboard that provides centralized access to all your investments.

Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Trevi Therapeutics. If investors know Trevi will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Trevi Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(0.44)

Return On Assets

(0.37)

Return On Equity

(0.60)

The market value of Trevi Therapeutics is measured differently than its book value, which is the value of Trevi that is recorded on the company's balance sheet. Investors also form their own opinion of Trevi Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Trevi Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Trevi Therapeutics' market value can be influenced by many factors that don't directly affect Trevi Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Trevi Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Trevi Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Trevi Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Trevi Historical Balance Sheet

Trevi Therapeutics Inventory

(263,292)

About Trevi Balance Sheet Analysis

Trevi Therapeutics Balance Sheet Chart

Total Assets

Total Current Liabilities

Current Deferred Revenue

Trevi Therapeutics balance sheet Correlations

Trevi Therapeutics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Trevi Therapeutics balance sheet Accounts

Currently Active Assets on Macroaxis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Current Assets	+ 1.0	Total Assets
Total Stockholder Equity	+ 0.98	Total Assets
Short Term Debt	+ 0.98	Total Current Liabilities
Total Current Assets	+ 0.98	Total Stockholder Equity
Property Plant Equipment	+ 0.97	Net Receivables
Property Plant And Equipment Net	+ 0.94	Other Current Assets

Net Tangible Assets	- 0.93	Other Liab
Retained Earnings	- 0.92	Net Tangible Assets
Non Currrent Assets Other	- 0.89	Short Long Term Debt
Other Current Assets	- 0.88	Retained Earnings
Accounts Payable	- 0.88	Other Liab
Retained Earnings	- 0.86	Total Assets